← Back to Blog
Announcement

Welcome to ClinicalInvestor: Making Biotech Investing Accessible

By ClinicalInvestor Team

Biotech stocks are some of the most exciting — and volatile — investments in the market. A single FDA decision can send a stock up 200% or down 80% overnight. Yet most of the tools and data that professional biotech investors rely on are locked behind expensive terminals and paywalls. ClinicalInvestor was built to change that.

What We Built

ClinicalInvestor is a free platform designed specifically for retail investors interested in clinical-stage biotech companies. We provide four core tools: a Catalyst Calendar that tracks every upcoming FDA decision and clinical trial readout, detailed Company Profiles breaking down pipeline assets and competitive positioning, Educational Guides that explain biotech investing concepts in plain English, and a Trial Translator that uses AI to convert complex clinical data into investor-friendly summaries.

Why This Matters

The biotech sector moves on data. PDUFA dates, Phase 3 readouts, Advisory Committee votes — these are the events that drive 20-60% stock moves. But finding and interpreting this information requires navigating FDA databases, SEC filings, ClinicalTrials.gov, and company press releases. We do that work so you can focus on making informed investment decisions.

Our Data Sources

Our sources are public: trial records come from ClinicalTrials.gov, financial figures from SEC filings, and FDA decision dates from the company announcement or filing that states them (the FDA itself publishes no calendar of pending decisions). Much of the analysis is drafted with AI assistance, and the site says so. A catalyst date that no primary source confirms is labelled as unconfirmed rather than shown as fact; our methodology page sets out exactly what is checked and what is not. (Corrected 2026-10-02: an earlier version of this post said PDUFA dates came directly from FDA.gov and that every data point was verified before publication. Neither was true.)

What Is Coming Next

We are actively building new features including an advanced stock screener with real-time filtering by PDUFA date proximity, trial phase, and therapeutic area. We are also expanding our educational content with weekly guides on topics like reading clinical trial data, understanding FDA approval pathways, and building a biotech portfolio. Stay tuned by subscribing to our newsletter.